TEL AVIV, Israel—Cellect Biotechnology Ltd. and the denovoMATRIX group of the Technische Universität Dresden announced a collaboration and material transfer agreement this summer. Per the agreement, the denovoMATRIX team will assess the synergy between Cellect’s ApoGraft technology and the denovoMATRIX technology to evaluate collaborative development of products for regenerative medicine, with a scientist from denovoMATRIX to conduct experiments at Cellect’s Israeli R&D site. A combination of their technologies is something the organizations feel could significantly enhance the stem cell selection and expansion process. Should the evaluation stage be deemed successful—which falls to Cellect’s discretion—the partners have both agreed to negotiate a potential mutual development agreement to develop a stem cell-related product.